This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce muscle fiber hypertrophy, as well as preserve skeletal muscle mass and physical performance up to 6 months after injury. Participants will be randomized in a 1:1 ratio to 1) standard of care (no dietary intervention) or 2) EAA-based supplementation.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Concentration and average count of satellite cells, myonuclei, M1, and M2 Macrophages for Type 1 and Type 2 fibers
Timeframe: Day of Surgery, 3 weeks
Cross sectional concentration of Type 1 and Type 2 muscle fibers
Timeframe: Day of Surgery, 3 weeks
Concentration of myostatin, interleukin-6, and tumor necrosis factor alpha
Timeframe: Day of Surgery, 3 weeks
Concentration of c-terminal agrin fragments
Timeframe: Day of Surgery, 3 weeks